Research & Development

  • Innovation and Competence

  • CONGEN is an innovative biotechnology company. Our core competencies include the design and validation of multiplex real-time PCR procedures. CONGEN is among the world leaders in this field. The goal of this method is to enable the detection of increasing numbers of targets using PCR methods within a single reaction vessel. Reliable multiplex detection methods allows clients to answer questions faster, simpler and more efficiently.

  • Over 300 detection methods
  • The solutions we develop are motivated either by clearly defined demands by our clients or by analytical problems that remain unsolved. At present, CONGEN is at work on solutions for applications in the following fields:

      • Clinical diagnostics
        • Stool diagnostics
        • Respiratory diagnostics
        • Nosocomial infections
        • Sexually transmitted diseases
        • Parodontitis diagnostics
      • Personalized medicine
        • Tumor therapy
        • Sepsis diagnostics
        • Metabolic disorders
        • Cardiovascular
        • Depression
      • Veterinary diagnostics
        • bacterial, viral and parasitic zoonotic pathogens

    We work with a network of partners from the research and industry sectors in order to find innovative solutions with product advantages over the state of the art.

    Are you interested in working together with us to develop new strategies for detection according to your own specifications? Are you planning a new research project and looking for a competent partner?  Contact us to discuss the possibilities.

  • 2016 CONGEN gladly receives the official seal “Innovative through Research” from the German Stifterverband

  • Product revenues

  • 75
  • 75 % of company turnover at CONGEN are realized through products that have been developed within the last three years.

  • Employee research and development

  • 25
  • 25 % of our employees are working at researching and developing new methods using the latest scientific findings.